{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063701","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.158593+00:00","generated_at":"2026-06-08T03:23:58.312945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kodiak Sciences Q3 net loss $50M; GLOW study shows tarcocimab 29-fold improvement","bullets":["Net loss $50.0M ($0.95/shr) vs $77.0M ($1.47) in Q3 2022; cash $345.7M.","R&D expenses fell to $36.2M from $61.7M due to development pause and forfeitures.","GLOW phase 3: 41.1% tarcocimab patients had ≥2-step DRSS improvement vs 1.4% sham (p<0.0001).","89% risk reduction in sight-threatening complications; plan to reboot tarcocimab for single BLA.","KSI-501 phase 1 enrollment complete; data expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063701","json":"https://secwatch.observer/filing/0000950170-23-063701.json","markdown":"https://secwatch.observer/filing/0000950170-23-063701.md","text":"https://secwatch.observer/filing/0000950170-23-063701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023063701/0000950170-23-063701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023063701/kod-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:23:58.312945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}